The assessment of pharmaceuticals for government subsidy in Australia: Recent developments

Journal of Medical Economics

Volumn 10, Issue 2, 2007, Pages 163-169

  Scuffham, Paul A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Economic evaluation; Guidelines; Pharmaceutical policy

Indexed keywords

AUSTRALIA; DEVELOPMENT; DRUG INDUSTRY; GOVERNMENT; REVIEW;

EID: 34447556865     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200710163169     Document Type: Review

References (14)

1. Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.1). www.health.gov. au/internet/wcms/publishing.nsf/Content/pbacguidelines-index. Accessed 02 Apr 2007.
2. Department of Health and Ageing. Expenditure and Prescriptions Twelve Months to 30 June 2006. www.health.gov. au/internet/wcms/publishing.nsf/ Content/pbs-stats-pbexp-jun06. Accessed 04 April 2007.
3. Department of Health and Ageing. Proforma for Estimates for PBAC Submissions Section 4. www.health.gov.au/internet/wcms/publishing.nsf/ Content/ PBAC_Submission_Proforma. Accessed 04 April 2007.
4. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. www.nice.org. uk/page.aspx?o=201974. Accessed 04 April 2007.
5. Commonwealth Department of Health and Ageing. Manual of Resource Items and their Associated Costs for Use in Submissions to the Pharmaceutical Benefits Advisory Committee Involving Economic Evaluation. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-general-pubs-manual-content. htm/$FILE/manual.pdf. Accessed 04 April 2007.
6. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 2001; 10(8): 779-787.
7. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Economics 2004; 13(5): 405-415.
8. Claxton K, Sculpher M, McCabe C et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005; 14(4): 339-347.
9. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 1999; 18: 342-364.
10. Beutels P, Viney RC. Comments on the Prosser et al approach to value disease reduction in children. Pediatrics 2004; 114(5): 1375; author reply 1375-1376.
11. Department of Health and Ageing. Australia-United States Free Trade Agreement. www.health.gov.au/ausfta. Accessed 06 April 2007.
12. Department of Health and Ageing. Public Summary Documents. www.health.gov. au/internet/wcms/publishing.nsf/Content/public-summary- documents. Accessed 06 April 2007.
13. NHS Health Technology Assessment Programme. NHS Health Technology Assessment Programme. www.hta.nhsweb. nhs.uk/nice/TARlisting.htm. Accessed 06 April 2007.
14. Department of Health and Ageing. Medical Services Advisory Committee Performance Report 2003-05. http://www.msac.gov. au/internet/msac/ publishing.nsf/Content/A8406798C7950179CA25715E0009810A/$File/ msacrep0305.pdf. Accessed 06 April 2007.